Skip to content

Will Sarepta Therapeutics’ Orphan Drug Eteplirsen For Duchenne Muscular Dystrophy Receive FDA Accelerated Approval: SeekingAlpha.com’s Perspective

November 20, 2012

       SeekingAlpha.com’s November 19, 2012 article titled, “Sarepta Ready To Move Higher”, is an interesting perspective on the hurdles and steps for receiving FDA Accelerated Approval, facing Sarepta Therapeutics’ orphan drug Eteplirsen, for the treatment of Duchenne Muscular Dystrophy (DMD). 

 Copyright © 2012-2013, Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: